Shopping Cart
- Remove All
Your shopping cart is currently empty
Physalin F is a natural blocker of CaV2.3 (R-type) and CaV2.2 (N-type) voltage-gated calcium channels.It is a secosteroid with potent anti-inflammatory and immunomodulatory activities. Physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by Human T-lymphotropic virus type 1 (HTLV-1) infection

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $45 | In Stock | |
| 5 mg | $89 | In Stock | |
| 10 mg | $129 | In Stock | |
| 25 mg | $219 | In Stock | |
| 50 mg | $326 | In Stock | |
| 100 mg | $485 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $122 | In Stock |
| Description | Physalin F is a natural blocker of CaV2.3 (R-type) and CaV2.2 (N-type) voltage-gated calcium channels.It is a secosteroid with potent anti-inflammatory and immunomodulatory activities. Physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by Human T-lymphotropic virus type 1 (HTLV-1) infection |
| In vitro | METHODS: Three renal cancer cell lines (A498, ACHN, and UO-31) were treated with physalin F (0, 0.3, 1, 3, and 10 μg/mL, 24 h), and cell viability was determined by MTT assay. RESULTS Physalin F inhibited cell viability in human renal cancer cell lines A498, ACHN, and UO-31 in a concentration-dependent manner with IC50 values of 1.40 μg/mL, 2.18 μg/mL, and 2.81 μg/mL, respectively. [3] METHODS: A498 cells were incubated in the absence or presence of physalin F (10 μg/mL, 6, 12, 18, 24 hours) for the indicated time, and the cells were harvested and prepared for detection of (A) mitochondrial membrane potential using FACScan analysis; A498 cells were incubated in the presence of physalin F (10 μg/mL, 3, 6, 8, 12, 18, 24 hours) for the indicated time, and the cells were harvested and prepared for detection of pro-caspase-8, 9, caspase-3, PARP, and p53, p21 expression using Western blotting. RESULTS The expression of Bcl-2 protein family including Bcl-2 and Bcl-xL was decreased after treatment with physalin F, and physalin F induced apoptosis of A498 cells through a mitochondria-dependent pathway; physalin F induced apoptosis by inducing p53 and p21 proteins, followed by cleavage of caspase-8/-9/-3 and PARP. [3] |
| In vivo | Physalin F is a secosteroid with potent anti-inflammatory and immunomodulatory activities.?A concentration-dependent inhibition of spontaneous proliferation of PBMC from HAM/TSP subjects was observed in the presence of physalin F, as evaluated by (3)H-thymidine uptake.?The IC50 for physalin F was 0.97 0.11 μM.?Flow cytometry analysis using Cytometric Bead Array (CBA) showed that physalin F (10 μM) significantly reduced the levels of IL-2, IL-6, IL-10, TNF-α and IFN-γ, but not IL-17A, in supernatants of PBMC cultures.?Next, apoptosis induction was addressed by using flow cytometry to evaluate annexin V expression.?Treatment with physalin F (10 μM) increased the apoptotic population of PBMC in HAM/TSP subjects.?Transmission electron microscopy analysis of PBMC showed that physalin F induced ultrastructural changes, such as pyknotic nuclei, damaged mitochondria, enhanced autophagic vacuole formation, and the presence of myelin-like figures.?In conclusion, physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by HTLV-1 infection. |
| Molecular Weight | 526.53 |
| Formula | C28H30O10 |
| Cas No. | 57423-71-9 |
| Smiles | [H][C@@]12C(=O)[C@]34O[C@@]11[C@](O)(CC[C@@]5([H])[C@@]3([H])C[C@H]3O[C@]33CC=CC(=O)[C@]53C)C(=O)O[C@@]1(C)[C@@]1([H])C[C@]2(C)[C@@]([H])(CO4)C(=O)O1 |
| Relative Density. | 1.58 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (113.95 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.9 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.